What the clinical research actually shows about MOTS-c safety Understanding the current state of clinical evidence helps calibrate expectations about what we know versus what remains uncertain about MOTS-c safety
Drucker, Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease, Endocrine Reviews, 2023, 44, 1432
C., Linssen, R
Certain conditions, such as medullary thyroid cancer history or pancreatitis, require alternative treatments
Bu elilerden biri olan GLP-1 (Glukagon Benzeri Peptid-1), vcudumuzun doal olarak rettii kymetli bir tokluk hormonudur
this reinforces the results of the current study where elevated TNF-, IL-1, and IL-6 were noticed in the liver following MTX challenge